Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Advances in Pharmacotherapy for Episodic Migraine
Calvin Chan, Peter J. Goadsby
CNS Drugs (2019) Vol. 33, Iss. 11, pp. 1053-1071
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
Antonio Russo, Marcello Silvestro, Fabrizio Scotto di Clemente, et al.
The Journal of Headache and Pain (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 121
Ubrogepant: First Approval
Lesley J. Scott
Drugs (2020) Vol. 80, Iss. 3, pp. 323-328
Open Access | Times Cited: 73
Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success
Gene M. Dubowchik, Charles M. Conway, Alison W. Xin
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 13, pp. 6600-6623
Closed Access | Times Cited: 66
Rimegepant: First Approval
Lesley J. Scott
Drugs (2020) Vol. 80, Iss. 7, pp. 741-746
Closed Access | Times Cited: 57
Atogepant: First Approval
Emma D. Deeks
Drugs (2021) Vol. 82, Iss. 1, pp. 65-70
Closed Access | Times Cited: 42
The role of erenumab in the treatment of migraine
Anna P. Andreou, Matteo Fuccaro, Giorgio Lambru
Therapeutic Advances in Neurological Disorders (2020) Vol. 13
Open Access | Times Cited: 32
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
Ivan Urits, Gavin Clark, Daniel An, et al.
Pain and Therapy (2020) Vol. 9, Iss. 1, pp. 195-215
Open Access | Times Cited: 28
A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial
Ramesh Boinpally, Brian McNamee, Yao Li, et al.
Clinical Pharmacology in Drug Development (2021) Vol. 10, Iss. 9, pp. 1099-1107
Open Access | Times Cited: 24
Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine
Min Shi, Jun Guo, Zhaoying Li, et al.
Neurological Research (2021) Vol. 43, Iss. 11, pp. 932-949
Closed Access | Times Cited: 17
Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine
Anand R. Shewale, Jennifer A. Brandenburg, Kate Burslem, et al.
Cephalalgia (2024) Vol. 44, Iss. 2
Open Access | Times Cited: 2
Pharmacological strategies to treat attacks of episodic migraine in adults
Peer Tfelt‐Hansen
Expert Opinion on Pharmacotherapy (2020) Vol. 22, Iss. 3, pp. 305-316
Closed Access | Times Cited: 18
Rimegepant for the treatment of migraine
Amnon A. Berger, Ariel Winnick, Austin H. Carroll, et al.
Health psychology research (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 10
Lasmiditan: an additional therapeutic option for the acute treatment of migraine
Daniele Martinelli, Vito Bitetto, Cristina Tassorelli
Expert Review of Neurotherapeutics (2021) Vol. 21, Iss. 5, pp. 491-502
Closed Access | Times Cited: 10
Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine
Zizhen Zhang, Yunfeng Shu, Yun Diao, et al.
Medicine (2021) Vol. 100, Iss. 8, pp. e24741-e24741
Open Access | Times Cited: 8
Devices for Episodic Migraine: Past, Present, and Future
David Moreno‐Ajona, Jan Hoffmann, Simon Akerman
Current Pain and Headache Reports (2022) Vol. 26, Iss. 3, pp. 259-265
Open Access | Times Cited: 5
Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.
Amnon A. Berger, Ariel Winnick, Daniel Popovsky, et al.
(2020) Vol. 50, pp. 163-188
Closed Access | Times Cited: 7
Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study
Bui Bao Khanh Dinh, Waseem Hamed Aziz, Alessandro Terruzzi, et al.
BMC Neurology (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 6
Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.
Amnon A. Berger, Ariel Winnick, Daniel Popovsky, et al.
PubMed (2020) Vol. 50, Iss. 4 Suppl 1, pp. 163-188
Closed Access | Times Cited: 6
Is the right way to go in between?
Andreas R. Gantenbein, Andreas Kleinschmidt
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Recent Advances in the Management of Cluster Headache
María Dolores Villar‐Martínez, Francesca Puledda, Peter J. Goadsby
Current Treatment Options in Neurology (2020) Vol. 22, Iss. 12
Open Access | Times Cited: 4
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
Lesley J. Scott
Drugs (2020) Vol. 80, Iss. 9, pp. 893-904
Closed Access | Times Cited: 2
Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review
Anna Ferrari, Cecilia Rustichelli
Clinical Therapeutics (2021) Vol. 43, Iss. 4, pp. 654-670
Closed Access | Times Cited: 2
Recomendações Terapêuticas para Cefaleias da Sociedade Portuguesa de Cefaleias – 2021
Elsa Parreira
Sinapse (2021) Vol. 21, Iss. supplement 1, pp. 3-100
Open Access | Times Cited: 2
Treatment
Paolo Martelletti
Springer eBooks (2022), pp. 639-881
Closed Access | Times Cited: 1
CE: Diagnosing and Managing Migraine
Allene Goetz, Samantha F. McCormick, Rosemary Phillips, et al.
AJN American Journal of Nursing (2021) Vol. 122, Iss. 1, pp. 32-43
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top